Respiratory Syncytial Virus is a growing health concern for Indian infants. Efforts for maternal RSV vaccine faces challenges ...

Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2R3, Canada Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada Department of ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

aNational Institute for Health and Care Research Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, UK bFaculty of Medicine ...

MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

ucl.ac.uk Respiratory syncytial virus (RSV) is the most common single cause of respiratory hospitalisation of infants and is the second largest cause of lower respiratory infection mortality worldwide ...

Respiratory Syncytial Virus (RSV) poses a significant threat to Indian infants, particularly during post-monsoon and winter, contributing substantially to bronchiolitis and pneumonia cases. While ...

on Wednesday to recommend that high-risk patients ages 50 to 59 be vaccinated for respiratory syncytial virus (RSV), and also added a new option for meningococcal vaccination. "I don't think I can ...

The aim of the study was to determine if the timing of respiratory virus testing using a RMDT in the ED had an association with patient care outcomes. Design Retrospective observational study. Setting ...

Respiratory syncytial virus (RSV) infection is the leading cause of hospitalisation for respiratory diseases among children under 5 years old. The aim of this study was to analyse RSV seasonality in ...